Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.63 USD | +5.20% | +11.91% | +12.88% |
04-04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
02-29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.88% | 35.25M | |
+25.95% | 661B | |
+26.74% | 566B | |
-6.65% | 352B | |
+19.35% | 332B | |
+3.36% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.17% | 145B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating